BioWorld

June 21, 2004

OSI's Prosidion Buying Diabetes Drug, Assets For At Least $35M

OSI Pharmaceuticals Inc. is acquiring substantially all the assets of one of its subsidiaries, Prosidion Ltd., in connection with the latter's purchase of a Phase II diabetes drug and related technology. (BioWorld Today) Read More

With Poor Data, Inflazyme To Drop LSAID In Asthma

FBI: Biotech Industry Not Facing Serious Problem' Of Extremists

After Reagan's Death, Pressure Mounts For Human ESC Reform

Guilford Licenses GPI 1485 To New Company Symphony

Other News To Note

Clarification

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026